Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy

Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027

Marks the third large state health plan signed through Amwell in the past 12 months, following contracts in Arizona and Florida

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives. The agreement was secured through Dario's strategic channel partnership with Amwell and is expected to launch and begin generating revenue in the first quarter of 2027.

The new agreement represents a significant expansion of Dario's reach into large health plan populations and further demonstrates the scalability of the Company's channel distribution strategy. As an administrative services only ("ASO") health plan, the customer provides Dario with the opportunity to access a large population of self-funded employer groups that will be able to deploy Dario's cardiometabolic solutions.

"This is exactly the type of scale we envisioned when we built our channel strategy," said Erez Raphael, Chief Executive Officer of Dario. "A single agreement gives Dario the opportunity to reach one and a half million covered lives through one of New Jersey's largest health plans, while our multi-condition platform and provider-backed care capabilities create opportunities to deliver even greater value within each employer customer relationship. Combined with DarioIQ's ability to personalize engagement at scale, this agreement brings together several growth drivers and demonstrates the compounding potential of the platform we have built."

The agreement further expands Dario's relationship with Amwell as a scalable distribution channel and stands in addition to previously secured contracts with major health insurers in Arizona and Florida. The addition of approximately 1.5 million covered lives through the New Jersey plan demonstrates the potential for channel partners to connect Dario with large payer populations while reducing reliance on a traditional direct-sales model.

Dario's integrated platform enables health plans and employers to address multiple chronic conditions through a single solution spanning diabetes, hypertension, weight management, musculoskeletal and behavioral health needs. Dario has also expanded its platform to include provider-backed clinical care, extending its capabilities from continuous digital engagement and chronic condition management through provider-led care.

About DarioHealth Corp.

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch of the program with the New Jersey health plan and the timing thereof; the expectation that the program will begin generating revenue in the first quarter of 2027; the ability of the agreement and the Company's relationship with Amwell to expand the Company's reach to covered lives and self-funded employer groups; the potential deployment of Dario's cardiometabolic solutions by such employer groups; and the scalability, growth potential and expected benefits of the Company's channel distribution strategy, platform and provider-backed care capabilities. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected] 
+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected] 

SOURCE DarioHealth Corp.